Compare FEMY & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEMY | ALLR |
|---|---|---|
| Founded | 2004 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2M | 19.3M |
| IPO Year | 2021 | 2021 |
| Metric | FEMY | ALLR |
|---|---|---|
| Price | $0.47 | $1.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $5.50 | ★ $9.75 |
| AVG Volume (30 Days) | ★ 363.1K | 130.6K |
| Earning Date | 05-08-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,293,313.00 | $320,000.00 |
| Revenue This Year | $105.16 | N/A |
| Revenue Next Year | $200.23 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 40.77 | N/A |
| 52 Week Low | $0.31 | $0.77 |
| 52 Week High | $1.16 | $2.35 |
| Indicator | FEMY | ALLR |
|---|---|---|
| Relative Strength Index (RSI) | 61.01 | 65.64 |
| Support Level | $0.33 | $1.47 |
| Resistance Level | $0.58 | $1.82 |
| Average True Range (ATR) | 0.03 | 0.09 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 94.53 | 73.68 |
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. Its product portfolio includes FemaSeed Intratubal Insemination, an infertility treatment; FemVue, a companion diagnostic for fallopian tube assessment via ultrasound; FemBloc, a clinical product candidate being developed as a permanent birth control; FemCerv, a tissue sampler for cervical cancer diagnosis; and FemCath and FemChec. Geographically, it derives key revenue from the United States and rest from international markets.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.